Lapatinib - Member of a new generation of ErbB-Targeting drugs

Breast Care

Volumn 5, Issue SUPPL. 1, 2010, Pages 8-12

  Untch, Michael ^a   Lück, Hans Joachim ^b  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b Gynäkologisch Onkologische Praxis Hannover   (Germany)

Author keywords

Dual tyrosine kinase inhibitor; EGF100151 study; Lapatinib; Trastuzumab resistance; Treatment beyond progression

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; LAPATINIB; PACLITAXEL; PLACEBO; TAXANE DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SURVIVAL TIME; TUMOR GROWTH;

EID: 77952838828     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000285750     Document Type: Review

References (18)

1. Moy B, Goss P: Lapatinib: current status and future directions in breast cancer. Oncologist 2006;11:1047-1057.
2. Johnston S, Leary A: Lapatinib: a novel EGFR/ HER2 tyrosine kinase inhibitor for cancer. Drugs Today 2006;42:441-453.
3. Burris HA 3rd: Dual kinase inhibition in the treatment of breast cancer. Initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004; 9(suppl 3):10-15.
4. Rusnak DW, Affleck K, Cockerill SG, et al.: The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001;61:7196-7203.
5. Nelson MH, Dolder CR: Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 2006;40:261-269.
6. Xia W, Liu LH, Ho P, Spector NL: Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004;23:646-653.
7. Anido J, Scaltriti M, Bech Serra JJ, et al.: Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 2006;25:3234-3244.
8. Geyer CE, Forster J, Lindquist D, et al.: Lapatinib plus capecitabine for HER-2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
9. Cameron D, Casey M, Press M, et al.: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-534.
10. Paul B, Trovato JA, Thompson J: Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. Am J Health Syst Pharm 2008;65:1703-1710.
11. Di Leo A, Gomez HL, Aziz Z, et al.: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26:5544-5552.
12. Von Minckwitz G, du Bois A, Schmidt M, et al.: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999-2006.
13. Jahanzeb M: Continuing trastuzumab beyond progression. J Clin Oncol 2009;27:1935-1937.
14. Valabrega G, Aglietta M: Trastuzumab beyond disease progression: case closed? J Clin Oncol 2009;27:e121-e122.
15. Crown J, Casey MA, Cameron D, Newstat B, Stein SH: Lapatinib (L) plus capecitabine (C) in HER2+ metastatic breast cancer (MBC): exploratory analyses by prior therapy. Eur J Cancer 2009; 7(suppl):abstr P-5082.
16. Scaltriti M, Rojo F, Ocaña A, et al.: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628-638.
17. Xia W, Liu LH, Ho P, Spector NL: Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004;23: 646-653.
18. Xia W, Husain I, Liu L, et al.: Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 2007;67:1170-1175.